News

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.

The authors noted that comparisons between PDA management strategies is crucial for informing optimal approaches to the PDA.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

Unlike conventional carrier screening that estimates generic reproductive risk, the UNITY panel offers a direct fetal risk estimate.

The data found complements state- and national-level CDC data, confirming widespread declines in MMR vaccination rates.

Children with blood lead levels below CDC intervention thresholds had lower test scores through adolescence, a new study showed.

The AI-enabled, wearable device is the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up.

Infant is closely monitored at subsequent well visits and rechecked after 3 months, showed full resolution of the skin lesion over the heel area.

Study results could guide future approaches to optimize service line definitions, according to the study authors.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Take a quick look at everything you may have missed last month, including the latest FDA updates, top stories, and exclusive interviews.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from May 2025.

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

With the new drug application accepted with priority review, the FDA has assigned a date of November 30, 2025, to complete its review for potential approval.

The hyperpolarized contrast agent for oral inhalation can now be used in patients 6 years and older, lowering the approved indication from 12 years of age.

Colleen Sloan, PA-C, RDN, shares some practical tips for providers and caregivers to help keep children hydrated during the summer.

Colleen Sloan, PA-C, RDN, highlights the connection between poor dietary patterns and mental health challenges in children, and offers nutrient-focused solutions.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

Victor Carrion, MD, explains how providers can recognize the signs of accumulated stress in children and support recovery through education and connection.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.

Review some of the reactions from experts about the recent FDA approval of roflumilast foam 0.3% to treat scalp and body psoriasis in patients aged 12 years or older.